Hypothesis

Senescent cells act as tissue chaperones not only through soluble SASP factors but also by releasing exosomes that transfer specific microRNAs and proteins to neighboring fibroblasts and macrophages, thereby maintaining a quiescent fibroblast state and promoting an anti‑fibrotic macrophage phenotype. Senolytic clearance removes these vesicular signals, leading to unchecked fibroblast activation and a shift toward pro‑fibrotic macrophages, which explains the observed worsening of fibrosis and delayed wound healing after indiscriminate senolytic treatment.

Rationale

The seed idea highlights that transient senescent cells are beneficial during acute injury, secreting growth factors such as PDGF‑AA to drive remodeling [2] and exhibiting developmental programs linked to regeneration [3]. Beyond paracrine cytokines, senescent cells are known to shed exosomes enriched in miR‑21, miR‑29, and TGF‑β‑smad7, which can suppress fibroblast‑to‑myofibroblast transition and inhibit collagen deposition in other contexts. When senescent cells persist, their SASP becomes pathogenic [4], but the exosomal cargo may still retain homeostatic functions that are lost upon senolytic‑induced depletion. Eliminating p16/p21‑positive cells during acute wound healing delays closure [5], suggesting that the removed cells contribute something essential beyond merely inflammatory signaling.

Testable Predictions

1. Exosomes isolated from young, transient senescent fibroblasts will contain a distinct miRNA signature (e.g., high miR‑29, low miR‑21) compared to exosomes from chronically senescent or non‑senescent fibroblasts.
2. Adding senescent‑cell‑derived exosomes to wounds of mice treated with a senolytic (e.g., navitoclax) will rescue the healing phenotype, reducing α‑SMA‑positive myofibroblasts and collagen I deposition to levels comparable with untreated controls.
3. Depleting exosomes from senescent cells (via GW4869 inhibition of neutral sphingomyelinase) prior to senolytic treatment will exacerbate fibrosis and delay wound closure even further than senolytic alone.
4. Macrophages exposed to senescent‑cell exosomes will exhibit increased expression of anti‑inflammatory markers (Arg1, Mrc1) and decreased pro‑fibrotic markers (Tgf‑β1, Pdgf‑bb) relative to macrophages exposed to exosomes from non‑senescent cells.

Experimental Approach

• Isolation: Culture young human fibroblasts, induce transient senescence with 2 Gy irradiation for 48 h, collect conditioned medium, and isolate exosomes by ultracentrifugation. Perform parallel isolates from chronically senescent fibroblasts (repeated passaging) and proliferating controls.
• Characterization: RNA‑seq of exosomal cargo to identify enriched miRNAs; validate by qPCR.
• In vivo model: Use 8‑week‑old C57BL/6 mice with full‑thickness dorsal excisional wounds. Treat groups with: (a) vehicle, (b) senolytic (navitoclax 50 mg/kg i.p. twice weekly), (c) senolytic + senescent‑cell exosomes (10 µg per wound daily), (d) senolytic + exosome‑depleted senescent‑cell conditioned medium (GW4869 pretreatment).
• Readouts: At days 4, 7, and 14 measure wound area, histology (Masson’s trichrome for collagen, α‑SMA immunostaining), and flow cytometry of wound‑resident macrophages (F4/80^+CD206^+ vs. F4/80^+CD86^+). Additionally, quantify exosomal miRNA levels in wound tissue via in situ hybridization.
• Falsification: If senescent‑cell exosomes fail to improve healing metrics or macrophage polarization in the senolytic‑treated wounds, the hypothesis is refuted. Conversely, a rescue effect supports the notion that vesicular signaling, not merely soluble SASP, underlies the chaperone function of transient senescent cells.

This framework directly extends the "chaperones and witnesses" metaphor by proposing a concrete molecular vehicle—exosomal cargo—that preserves tissue architecture, and it offers a clear, falsifiable path to test whether preserving or mimicking this vesicular communication can uncouple the beneficial roles of senescence from its detrimental chronic accumulation.